Search for a report

Reports

  • You are here:
  • Home
  • Downloads
  • ASIA PACIFIC OPHTHALMIC DRUG MARKET FORECAST 2019-2027

ASIA PACIFIC OPHTHALMIC DRUG MARKET FORECAST 2019-2027

Asia Pacific ophthalmic drugs & devices market was valued at $XX million in 2018 and is expected to reach $XX million by 2027 growing at a CAGR of 4.86% during the forecast period of 2019-2027. The ophthalmic drugs and devices market is driven by an increase in FDA approvals which gives a boost in the adoption of drugs and devices and rise in surgeries in ophthalmology market due to the high dominance of refractive errors.

ASIA PACIFIC OPHTHALMIC DRUG MARKET FORECAST 2019-2027

Asia Pacific Ophthalmic Drug Market by Indication (Dry Eye, Glaucoma, Infection/inflammation/allergy, Retinal Disorders, Other Indication) by Type (Prescription Drugs, Over-the-counter Drugs) by Distribution Channel (Hospital Pharmacies, Drug Stores, Online Pharmacies, Other Distribution Channel) by Dosage Form (Liquid Ophthalmic Drug Forms, Solid Ophthalmic Drug Forms, Semisolid Ophthalmic Drug Forms, Multicompartment Drug Delivery Systems, Other Ophthalmic Drug Forms) by Therapeutic Class (Anti-glaucoma, Anti-infective, Anti-inflammatory, Anti-allergy) by Technology (Biologics, Cell Therapy, Gene Therapy, Drug Delivery, Small Molecule, Other Technology)

Request free sample

Report Summary

Asia Pacific ophthalmic drugs & devices market was valued at $XX million in 2018 and is expected to reach $XX million by 2027 growing at a CAGR of 4.86% during the forecast period of 2019-2027. The ophthalmic drugs and devices market is driven by an increase in FDA approvals which gives a boost in the adoption of drugs and devices and rise in surgeries in ophthalmology market due to the high dominance of refractive errors.

The countries analyzed in the Asia-Pacific region are India, China, Japan, South Korea, Australia and the Rest of APAC. Globally increase in geriatric population, rise in the number of eye disorders, increase in healthcare expenditure and rise in adoption of minimally invasive surgeries have contributed to the growth of the market.

Well-known drugs are going off patent and key players affected by the delay in new drugs coming into the market are the two factors restricting the growth of the market. The market faces challenges in risk associated with the ocular diseases and lack of awareness among people regarding ophthalmology.

Global ophthalmic drugs market has a large number of market players but the market is dominated by companies like Sun Pharmaceuticals Industries, Ltd., GlaxoSmithKline, Cipla Pharmaceuticals, Novartis AG, Allergan Inc., Regeneron, Bayer, Abbott Laboratories, Senju Pharmaceutical Co., Ltd., Johnson and Johnson, Pfizer Inc., Roche Holding AG, Apollo Endosurgery, Valeant, Merck & Co., and Eyegate Pharmaceuticals.

 

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


    Table of Contents

    1. RESEARCH SCOPE
      • STUDY GOALS
      • SCOPE OF THE MARKET STUDY
      • WHO WILL FIND THIS REPORT USEFUL?
      • STUDY AND FORECASTING YEARS
    2. RESEARCH METHODOLOGY
      • SOURCES OF DATA
        • SECONDARY DATA
        • PRIMARY DATA
      • TOP-DOWN APPROACH
      • BOTTOM-UP APPROACH
      • DATA TRIANGULATION
    3. EXECUTIVE SUMMARY
      • MARKET SUMMARY
      • KEY FINDINGS
        • RETINAL DISORDERS ARE THE HIGHEST REVENUE GENERATING INDICATION
        • PRESCRIPTION DRUGS ARE THE FASTEST GROWING OPHTHALMIC DRUGS TYPE
        • HOSPITAL PHARMACIES ARE THE MAJORLY USED DISTRIBUTION CHANNEL
        • LIQUID OPHTHALMIC DRUG FORMS ARE THE WIDELY USED DOSAGE FORM
        • ANTI-ALLERGY THERAPEUTIC CLASS IS ANTICIPATED TO GROW AT A SIGNIFICANT RATE DURING THE FORECAST PERIOD
        • SMALL MOLECULE TECHNOLOGY IS USED FOR THE TREATMENT OF EYE DISEASES
    1. MARKET DETERMINANTS
      • MARKET DEFINITION AND SCOPE
      • MARKET DRIVERS
        • INCREASING GERIATRIC POPULATION
        • TECHNOLOGICAL ADVANCEMENT
        • RISING PREVALENCE OF EYE DISORDERS
        • INCREASED HEALTHCARE EXPENDITURE
      • MARKET RESTRAINTS
        • RENOWNED DRUGS GOING OFF-PATENT
        • DELAY IN DRUG APPROVALS
      • MARKET OPPORTUNITIES
        • INCREASE IN DISORDER SYMPTOM AND IMPROVED DIAGNOSIS LEADING TO HIGHER TREATMENT RATES
        • GROWING OPPORTUNITIES IN DEVELOPING ECONOMIES
      • MARKET CHALLENGES
        • SIDE EFFECTS RELATED TO THE OPHTHALMIC DRUGS
    1. MARKET BY INDICATION
      • DRY EYE
      • GLAUCOMA
      • INFECTION/INFLAMMATION/ALLERGY
      • RETINAL DISORDERS
        • WET AGE-RELATED MACULAR DEGENERATION
        • DRY AGE-RELATED MACULAR DEGENERATION
        • DIABETIC RETINOPATHY
        • OTHER RETINAL DISORDERS
      • OTHER INDICATION
    2. MARKET BY TYPE
      • PRESCRIPTION DRUGS
      • OVER-THE-COUNTER DRUGS
    3. MARKET BY DISTRIBUTION CHANNEL
      • HOSPITAL PHARMACIES
      • DRUG STORES
      • ONLINE PHARMACIES
      • OTHER DISTRIBUTION CHANNEL
    4. MARKET BY DOSAGE FORM
      • LIQUID OPHTHALMIC DRUG FORMS
      • SOLID OPHTHALMIC DRUG FORMS
      • SEMISOLID OPHTHALMIC DRUG FORMS
      • MULTICOMPARTMENT DRUG DELIVERY SYSTEMS
      • OTHER OPHTHALMIC DRUG FORMS
    5. MARKET BY THERAPEUTIC CLASS
      • ANTI-GLAUCOMA
      • ANTI-INFECTIVE
      • ANTI-INFLAMMATORY
      • ANTI-ALLERGY
    6. MARKET BY TECHNOLOGY
      • BIOLOGICS
      • CELL THERAPY
      • GENE THERAPY
      • DRUG DELIVERY
      • SMALL MOLECULE
      • OTHER TECHNOLOGY
    7. KEY ANALYTICS
      • PORTER’S FIVE FORCES ANALYSIS
        • BARGAINING POWER OF BUYERS
        • BARGAINING POWER OF SUPPLIER
        • THREATS OF NEW ENTRANTS
        • THREATS OF SUBSTITUTES
        • COMPETITIVE RIVALRY
      • VALUE CHAIN ANALYSIS
        • RESEARCH AND DEVELOPMENT
        • MANUFACTURING
        • MARKETING AND DISTRIBUTION
      • REGULATORY FRAMEWORK
      • OPPORTUNITY MATRIX
    8. GEOGRAPHICAL ANALYSIS
      • ASIA PACIFIC
        • CHINA
        • INDIA
        • JAPAN
        • SOUTH KOREA
        • AUSTRALIA
        • REST OF ASIA PACIFIC
    1. COMPANY PROFILES
      • ABBOTT LABORATORIES
      • ALLERGAN INC.
      • JOHNSON AND JOHNSON
      • BAYER
      • VALEANT
      • REGENERON
      • PFIZER INC.
      • MERCK & CO.
      • NOVARTIS AG
      • GLAXOSMITHKLINE
      • EYEGATE PHARMACEUTICALS
      • APOLLO ENDOSURGERY
      • ROCHE HOLDING AG
      • CIPLA PHARMACEUTICALS
      • SENJU PHARMACEUTICAL CO., LTD.
      • SUN PHARMACEUTICALS INDUSTRIES, LTD.

     

     TABLE LIST

    TABLE 1        ASIA PACIFIC OPHTHALMIC DRUG MARKET REVENUE 2019-2027 ($ MILLION)

    TABLE 2        COMMON CAUSES OF LOSS OF VISION IN THE ELDERLY

    TABLE 3        EYE DRUGS GONE OFF-PATENT

    TABLE 4        ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY INDICATION 2019-2027 ($ MILLION)

    TABLE 5        ASIA PACIFIC DRY EYE MARKET 2019-2027 ($ MILLION)

    TABLE 6        ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY DRY EYE 2019-2027 ($ MILLION)

    TABLE 7        ASIA PACIFIC GLAUCOMA MARKET 2019-2027 ($ MILLION)

    TABLE 8        ASIA PACIFIC INFECTION/INFLAMMATION/ALLERGY MARKET 2019-2027 ($ MILLION)

    TABLE 9        ASIA PACIFIC RETINAL DISORDERS MARKET 2019-2027 ($ MILLION)

    TABLE 10      ASIA PACIFIC WET AGE-RELATED MACULAR DEGENERATION MARKET 2019-2027 ($ MILLION)

    TABLE 11      ASIA PACIFIC DRY AGE-RELATED MACULAR DEGENERATION MARKET 2019-2027 ($ MILLION)

    TABLE 12      ASIA PACIFIC DIABETIC RETINOPATHY MARKET 2019-2027 ($ MILLION)

    TABLE 13      ASIA PACIFIC OTHER RETINAL DISORDERS MARKET 2019-2027 ($ MILLION)

    TABLE 14      ASIA PACIFIC OTHER INDICATION MARKET 2019-2027 ($ MILLION)

    TABLE 15      ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY TYPE 2019-2027 ($ MILLION)

    TABLE 16      ASIA PACIFIC PRESCRIPTION DRUGS MARKET 2019-2027 ($ MILLION)

    TABLE 17      ASIA PACIFIC OVER-THE-COUNTER DRUGS MARKET 2019-2027 ($ MILLION)

    TABLE 18      ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY DISTRIBUTION CHANNEL 2019-2027 ($ MILLION)

    TABLE 19      ASIA PACIFIC HOSPITAL PHARMACIES MARKET 2019-2027 ($ MILLION)

    TABLE 20      ASIA PACIFIC DRUG STORES MARKET 2019-2027 ($ MILLION)

    TABLE 21      ASIA PACIFIC ONLINE PHARMACIES MARKET 2019-2027 ($ MILLION)

    TABLE 22      ASIA PACIFIC OTHER DISTRIBUTION CHANNEL MARKET 2019-2027 ($ MILLION)

    TABLE 23      ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY DOSAGE FORM 2019-2027 ($ MILLION)

    TABLE 24      ASIA PACIFIC LIQUID OPHTHALMIC DRUG FORMS PHARMACIES MARKET 2019-2027 ($ MILLION)

    TABLE 25      ASIA PACIFIC SOLID OPHTHALMIC DRUG FORMS MARKET 2019-2027 ($ MILLION)

    TABLE 26      ASIA PACIFIC SEMISOLID OPHTHALMIC DRUG FORMS MARKET 2019-2027 ($ MILLION)

    TABLE 27      ASIA PACIFIC MULTICOMPARTMENT DRUG DELIVERY SYSTEMS MARKET 2019-2027 ($ MILLION)

    TABLE 28      ASIA PACIFIC OTHER OPHTHALMIC DRUG FORMS MARKET 2019-2027 ($ MILLION)

    TABLE 29      ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY THERAPEUTIC CLASS 2019-2027 ($ MILLION)

    TABLE 30      ASIA PACIFIC ANTI-GLAUCOMA MARKET 2019-2027 ($ MILLION)

    TABLE 31      ASIA PACIFIC ANTI-INFECTIVE MARKET 2019-2027 ($ MILLION)

    TABLE 32      ASIA PACIFIC ANTI-INFLAMMATORY MARKET 2019-2027 ($ MILLION)

    TABLE 33      ASIA PACIFIC ANTI-ALLERGY MARKET 2019-2027 ($ MILLION)

    TABLE 34      ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY TECHNOLOGY 2019-2027 ($ MILLION)

    TABLE 35      ASIA PACIFIC BIOLOGICS MARKET 2019-2027 ($ MILLION)

    TABLE 36      ASIA PACIFIC CELL THERAPY MARKET 2019-2027 ($ MILLION)

    TABLE 37      ASIA PACIFIC GENE THERAPY MARKET 2019-2027 ($ MILLION)

    TABLE 38      ASIA PACIFIC DRUG DELIVERY MARKET 2019-2027 ($ MILLION)

    TABLE 39      ASIA PACIFIC SMALL MOLECULE MARKET 2019-2027 ($ MILLION)

    TABLE 40      ASIA PACIFIC OTHER TECHNOLOGY MARKET 2019-2027 ($ MILLION)

    TABLE 41      ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY COUNTRY 2019-2027 ($ MILLION)

    FIGURES LIST

    FIGURE 1      ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY GLAUCOMA2019-2027 ($ MILLION)

    FIGURE 2      ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY INFECTION/INFLAMMATION/ALLERGY 2019-2027 ($ MILLION)

    FIGURE 3      ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY RETINAL DISORDERS 2019-2027 ($ MILLION)

    FIGURE 4      ASIA PACIFIC RETINAL DISORDERS MARKET BY WET AGE-RELATED MACULAR DEGENERATION 2019-2027 ($ MILLION)

    FIGURE 5      ASIA PACIFIC RETINAL DISORDERS MARKET BY DRY AGE-RELATED MACULAR DEGENERATION 2019-2027 ($ MILLION)

    FIGURE 6      ASIA PACIFIC RETINAL DISORDERS MARKET BY DIABETIC RETINOPATHY 2019-2027 ($ MILLION)

    FIGURE 7      ASIA PACIFIC RETINAL DISORDERS MARKET BY OTHER RETINAL DISORDERS 2019-2027 ($ MILLION)

    FIGURE 8      ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY OTHER INDICATION 2019-2027 ($ MILLION)

    FIGURE 9      ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY PRESCRIPTION DRUGS 2019-2027 ($ MILLION)

    FIGURE 10   ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY OVER-THE-COUNTER DRUGS 2019-2027 ($ MILLION)

    FIGURE 11   ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY HOSPITAL PHARMACIES 2019-2027 ($ MILLION)

    FIGURE 12   ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY DRUG STORES 2019-2027 ($ MILLION)

    FIGURE 13   ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY ONLINE PHARMACIES 2019-2027 ($ MILLION)

    FIGURE 14   ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY OTHER DISTRIBUTION CHANNEL 2019-2027 ($ MILLION)

    FIGURE 15   ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY LIQUID OPHTHALMIC DRUG FORMS 2019-2027 ($ MILLION)

    FIGURE 16   ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY SOLID OPHTHALMIC DRUG FORMS 2019-2027 ($ MILLION)

    FIGURE 17   ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY SEMISOLID OPHTHALMIC DRUG FORMS 2019-2027 ($ MILLION)

    FIGURE 18   ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY MULTICOMPARTMENT DRUG DELIVERY SYSTEMS 2019-2027 ($ MILLION)

    FIGURE 19   ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY OTHER OPHTHALMIC DRUG FORMS 2019-2027 ($ MILLION)

    FIGURE 20   ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY ANTI-GLAUCOMA 2019-2027 ($ MILLION)

    FIGURE 21   ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY ANTI-INFECTIVE 2019-2027 ($ MILLION)

    FIGURE 22   ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY ANTI-INFLAMMATORY 2019-2027 ($ MILLION)

    FIGURE 23   ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY ANTI-ALLERGY 2019-2027 ($ MILLION)

    FIGURE 24   ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY BIOLOGICS 2019-2027 ($ MILLION)

    FIGURE 25   ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY CELL THERAPY 2019-2027 ($ MILLION)

    FIGURE 26   ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY GENE THERAPY 2019-2027 ($ MILLION)

    FIGURE 27   ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY DRUG DELIVERY 2019-2027 ($ MILLION)

    FIGURE 28   ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY SMALL MOLECULE 2019-2027 ($ MILLION)

    FIGURE 29   ASIA PACIFIC OPHTHALMIC DRUGS MARKET BY OTHER TECHNOLOGY 2019-2027 ($ MILLION)

    FIGURE 30   ASIA PACIFIC OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE 31   CHINA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE 32   INDIA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE 33   JAPAN OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE 34   SOUTH KOREA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE 35   NUMBER OF YEARS IN PERCENTAGE, AGED 65 AND ABOVE IN TOTAL POPULATION TO TRIPLE

    FIGURE 36   AUSTRALIA OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

    FIGURE 37   REST OF ASIA PACIFIC OPHTHALMIC DRUGS MARKET 2019-2027 ($ MILLION)

    Segmentation

    1. GEOGRAPHICAL ANALYSIS
      • ASIA PACIFIC
        • CHINA
        • INDIA
        • JAPAN
        • SOUTH KOREA
        • AUSTRALIA
        • REST OF ASIA PACIFIC
    1. MARKET BY INDICATION
      • DRY EYE
      • GLAUCOMA
      • INFECTION/INFLAMMATION/ALLERGY
      • RETINAL DISORDERS
        • WET AGE-RELATED MACULAR DEGENERATION
        • DRY AGE-RELATED MACULAR DEGENERATION
        • DIABETIC RETINOPATHY
        • OTHER RETINAL DISORDERS
      • OTHER INDICATION
    2. MARKET BY TYPE
      • PRESCRIPTION DRUGS
      • OVER-THE-COUNTER DRUGS
    3. MARKET BY DISTRIBUTION CHANNEL
      • HOSPITAL PHARMACIES
      • DRUG STORES
      • ONLINE PHARMACIES
      • OTHER DISTRIBUTION CHANNEL
    4. MARKET BY DOSAGE FORM
      • LIQUID OPHTHALMIC DRUG FORMS
      • SOLID OPHTHALMIC DRUG FORMS
      • SEMISOLID OPHTHALMIC DRUG FORMS
      • MULTICOMPARTMENT DRUG DELIVERY SYSTEMS
      • OTHER OPHTHALMIC DRUG FORMS
    5. MARKET BY THERAPEUTIC CLASS
      • ANTI-GLAUCOMA
      • ANTI-INFECTIVE
      • ANTI-INFLAMMATORY
      • ANTI-ALLERGY
    6. MARKET BY TECHNOLOGY
      • BIOLOGICS
      • CELL THERAPY
      • GENE THERAPY
      • DRUG DELIVERY
      • SMALL MOLECULE
      • OTHER TECHNOLOGY

    Request Free Sample

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


      Choose License Type

      RELATED REPORTS

      Author: shalini amarnani